ArticleTranslational lung cancer research2018

Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50.

Paul Zarogoulidis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.